The estimated Net Worth of Miriam Kidron is at least $3.18 Million dollars as of 14 March 2023. Miriam Kidron owns over 100,000 units of Oramed Pharmaceuticals, Inc stock worth over $479,965 and over the last 17 years he sold ORMP stock worth over $2,086,920. In addition, he makes $616,166 as Chief Scientific Officer and Director at Oramed Pharmaceuticals, Inc.
Miriam has made over 8 trades of the Oramed Pharmaceuticals, Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 100,000 units of ORMP stock worth $201,000 on 14 March 2023.
The largest trade he's ever made was exercising 142,814 units of Oramed Pharmaceuticals, Inc stock on 1 August 2014 worth over $1,428. On average, Miriam trades about 21,877 units every 117 days since 2007. As of 14 March 2023 he still owns at least 201,666 units of Oramed Pharmaceuticals, Inc stock.
You can see the complete history of Miriam Kidron stock trades at the bottom of the page.
Dr. Miriam Kidron Ph.D. serves as Chief Scientific Officer, Director of the Company. Dr. Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. During 2003 and 2004, Dr. Kidron served as a consultant to Emisphere Technologies Inc., a company that specializes in developing broad-based proprietary drug delivery platforms. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award.
As the Chief Scientific Officer and Director of Oramed Pharmaceuticals, Inc, the total compensation of Miriam Kidron at Oramed Pharmaceuticals, Inc is $616,166. There are 2 executives at Oramed Pharmaceuticals, Inc getting paid more, with Nadav Kidron having the highest compensation of $1,551,100.
Miriam Kidron is 79, he's been the Chief Scientific Officer and Director of Oramed Pharmaceuticals, Inc since 2006. There are 2 older and 12 younger executives at Oramed Pharmaceuticals, Inc. The oldest executive at Oramed Pharmaceuticals, Inc is Dr. Miriam Kidron Ph.D., 81, who is the Chief Scientific Officer & Director.
Miriam's mailing address filed with the SEC is 2 ELZA STREET, , JERUSALEM, L3, 93706.
Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over $7,377,390 worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth $3,583,418 . The most active insiders traders include Miriam Kidron, Leonard Sank, and Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of $97,149. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth $19,556.
oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg
Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include: